CY1113345T1 - Μεθοδος και συστημα για την αφαιρεση διαλυτων tnfr1, tnfr2, και il2r σε ασθενεις - Google Patents
Μεθοδος και συστημα για την αφαιρεση διαλυτων tnfr1, tnfr2, και il2r σε ασθενειςInfo
- Publication number
- CY1113345T1 CY1113345T1 CY20121101098T CY121101098T CY1113345T1 CY 1113345 T1 CY1113345 T1 CY 1113345T1 CY 20121101098 T CY20121101098 T CY 20121101098T CY 121101098 T CY121101098 T CY 121101098T CY 1113345 T1 CY1113345 T1 CY 1113345T1
- Authority
- CY
- Cyprus
- Prior art keywords
- patients
- sll2r
- stnfr2
- stnfr1
- il2r
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3403—Regulation parameters
- A61M1/3406—Physical characteristics of the filtrate, e.g. urea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3482—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
- A61M1/3489—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents by biological cells, e.g. bioreactor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
- A61M1/3689—Chemical treatment by biological cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- External Artificial Organs (AREA)
Abstract
Έχει αναπτυχθεί σύστημα για την πρόκληση της υποχώρησης σε ασθένειες που χαρακτηρίζονται από την υπερβολική παραγωγή των διαλυτών υποδοχέων TNF (sTNFR) και των διαλυτών υποδοχέων ιντερλευκίνης 2 (slL2R). Στην πλέον προτιμώμενη ενσωμάτωση, το σύστημα αποτελείται από αντισώματα σε sTNFR1, sTNFR2 και slL2R που ακινητοποιούνται σε μια στήλη που περιέχει ένα υλικό όπως Sepharose™. Ο ασθενής συνδέεται με μια μηχανή αφαίρεσης που διαχωρίζει το αίμα στο πλάσμα και τα ερυθρά κύτταρα και το πλάσμα κυκλοφορεί μέσω της στήλης μέχρι να επιτευχθεί η επιθυμητή μείωση των επιπέδων των sTNFR1, sTNFR2 και slL2R, κατά προτίμηση κάτω από τα κανονικά επίπεδα. Κατά προτίμηση, οι ασθενείς υποβάλλονται σε θεραπεία τρεις φορές εβδομαδιαίως για τέσσερις εβδομάδες και αυτό μπορεί να επαναληφθεί μετά από μια περίοδο χρόνου. Οι κλινικές μελέτες παρουσίασαν μείωση του φορτίου του όγκου στους ασθενείς που έχουν αποτύχει με τη συμβατική χημειοθεραπεία και τις θεραπείες ακτινοβολίας.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56674104P | 2004-04-30 | 2004-04-30 | |
EP08007944A EP1949915B1 (en) | 2004-04-30 | 2005-04-29 | Method and system to remove soluble TNFR1, TNFR2, and IL2R in patients |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113345T1 true CY1113345T1 (el) | 2016-06-22 |
Family
ID=35320738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121101098T CY1113345T1 (el) | 2004-04-30 | 2012-11-14 | Μεθοδος και συστημα για την αφαιρεση διαλυτων tnfr1, tnfr2, και il2r σε ασθενεις |
Country Status (17)
Country | Link |
---|---|
US (6) | US20050265996A1 (el) |
EP (2) | EP1740209A2 (el) |
JP (1) | JP2008511340A (el) |
CN (1) | CN1980696B (el) |
AU (2) | AU2005240082B2 (el) |
CA (1) | CA2565215C (el) |
CY (1) | CY1113345T1 (el) |
DK (1) | DK1949915T3 (el) |
ES (1) | ES2393637T3 (el) |
HK (1) | HK1125026A1 (el) |
IL (2) | IL178845A (el) |
IN (1) | IN2009DN07374A (el) |
PL (1) | PL1949915T3 (el) |
PT (1) | PT1949915E (el) |
RU (1) | RU2378016C2 (el) |
SI (1) | SI1949915T1 (el) |
WO (1) | WO2005107802A2 (el) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8197430B1 (en) | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
US6620382B1 (en) * | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
AU2005240082B2 (en) * | 2004-04-30 | 2009-07-23 | Innatus Corporation | Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients |
AU2005269820B2 (en) * | 2004-07-22 | 2009-03-26 | Early Detection Llc | Methods for diagnosis using anti-cytokine receptor antibodies |
US7918863B2 (en) * | 2005-06-24 | 2011-04-05 | Conceptus, Inc. | Minimally invasive surgical stabilization devices and methods |
EP1951336A2 (en) * | 2005-07-18 | 2008-08-06 | The Trustees Of Boston University | Method to inhibit proliferation and growth of metastases |
CA2644855C (en) * | 2006-03-09 | 2019-11-19 | Aethlon Medical, Inc. | Extracorporeal removal of microvesicular particles |
US20080269762A1 (en) * | 2007-04-25 | 2008-10-30 | Biomet Manufacturing Corp. | Method and device for repair of cartilage defects |
AU2008293431B2 (en) * | 2007-08-31 | 2013-07-04 | Cytopherx, Inc. | Selective cytopheresis devices and related methods thereof |
JP2009178523A (ja) * | 2008-02-01 | 2009-08-13 | Kaneka Corp | 可溶性腫瘍壊死因子受容体の吸着材、吸着方法および吸着装置 |
US8753690B2 (en) * | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
EP2567692B1 (en) | 2008-02-27 | 2016-04-06 | Biomet Biologics, LLC | Use of a device for obtaining interleukin-1 receptor antagonist rich solutions |
US8905760B2 (en) * | 2008-11-04 | 2014-12-09 | Duane C. Keller | Methods and systems for progressively treating and controlling oral periopathogens causing systemic inflammations |
US8758287B2 (en) | 2008-11-12 | 2014-06-24 | Marv Enterprises, LLC | Utilization of stents for the treatment of blood borne carcinomas |
JP5249737B2 (ja) * | 2008-12-10 | 2013-07-31 | 旭化成メディカル株式会社 | 血液からウイルス及びサイトカインを除去するシステム |
US8454547B2 (en) | 2009-02-25 | 2013-06-04 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
WO2010107789A1 (en) * | 2009-03-17 | 2010-09-23 | Marv Enterprises Llc | Sequential extracorporeal treatment of bodily fluids |
JP5844258B2 (ja) | 2009-08-27 | 2016-01-13 | バイオメット、バイオロジクス、リミテッド、ライアビリティー、カンパニーBiomet Biologics, Llc | インターロイキン−1受容体アンタゴニストの生産のための植込み型装置 |
US20110052561A1 (en) * | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
EP2569253A4 (en) * | 2010-05-14 | 2013-10-02 | Beth Israel Hospital | EXTRACORPOREAL DEVICES AND METHODS FOR TREATING PREGNANCY COMPLICATIONS |
WO2012030593A2 (en) | 2010-09-03 | 2012-03-08 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
CA2814586C (en) | 2010-10-15 | 2024-01-30 | Cytopherx, Inc. | Cytopheretic cartridge and use thereof |
JP2014503187A (ja) | 2010-10-29 | 2014-02-13 | ノクソン ファーマ エージー | 身体からヘプシジンを除去するためのヘプシジン結合核酸の使用 |
US20130131423A1 (en) * | 2011-04-12 | 2013-05-23 | Tianxin Wang | Methods to detect and treat diseases |
US9867923B2 (en) | 2011-05-09 | 2018-01-16 | University Of Miami | Reducing soluble urokinase receptor in the circulation |
US9138343B2 (en) | 2011-05-31 | 2015-09-22 | Bayer Healthcare Llc | Tip protector sleeve |
WO2012163544A1 (en) | 2011-06-01 | 2012-12-06 | Biopheresis Technologies, Inc. | Removal of soluble tumor necrosis factor receptor 2 (stnfr2) |
US8792693B2 (en) * | 2011-07-09 | 2014-07-29 | Gauss Surgical | System and method for estimating extracorporeal blood volume in a physical sample |
US10426356B2 (en) | 2011-07-09 | 2019-10-01 | Gauss Surgical, Inc. | Method for estimating a quantity of a blood component in a fluid receiver and corresponding error |
CA2852220A1 (en) | 2011-10-14 | 2013-07-18 | Cytopherx, Inc. | Cartridge and method for increasing myocardial function |
US9549953B2 (en) * | 2011-12-08 | 2017-01-24 | Eliaz Therapeutics, Inc. | Galectin-3 plasmapheresis therapy |
US8764695B2 (en) * | 2012-09-28 | 2014-07-01 | Isaac Eliaz | Reduction of galectin-3 levels by plasmapheresis |
US20150027950A1 (en) * | 2012-03-27 | 2015-01-29 | Marv Enterprises, LLC | Treatment for atherosclerosis |
EP2850559B1 (en) | 2012-05-14 | 2021-02-24 | Gauss Surgical, Inc. | System and method for estimating a quantity of a blood component in a fluid canister |
CN104661582B (zh) | 2012-05-14 | 2018-07-27 | 高斯外科公司 | 处理患者失血的系统与方法 |
WO2013179143A2 (en) | 2012-06-01 | 2013-12-05 | Biopheresis Technologies, Inc. | Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors |
US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
EP2970490A4 (en) | 2013-03-15 | 2017-04-26 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
JP6513668B2 (ja) * | 2013-08-12 | 2019-05-15 | ヘルス リサーチ インコーポレイテッドHealth Research, Inc. | 前立腺癌のバイオマーカー |
EP3074507B1 (en) | 2013-11-26 | 2022-01-05 | Biomet Biologics, LLC | Methods of mediating macrophage phenotypes |
EP3086870B1 (en) * | 2013-12-27 | 2019-01-02 | Eliaz Therapeutics, Inc. | Plasmapheresis device |
US20170038382A1 (en) * | 2014-01-24 | 2017-02-09 | Ntercept, Llc | Methods and compositions for immune dis-inhibition |
EA035898B1 (ru) * | 2014-10-03 | 2020-08-28 | НАНОТИКС, ЭлЭлСи | Композиции и способы для ингибирования биологической активности растворимых биомолекул |
US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
EP3274010B1 (en) * | 2015-03-27 | 2019-10-02 | Eliaz Therapeutics, Inc. | Patient selective apheresis |
CN104815360A (zh) * | 2015-04-14 | 2015-08-05 | 复旦大学 | 循环肿瘤细胞过滤治疗仪 |
WO2016187071A1 (en) | 2015-05-15 | 2016-11-24 | Gauss Surgical, Inc. | Systems and methods for assessing fluids from a patient |
WO2016187072A1 (en) | 2015-05-15 | 2016-11-24 | Gauss Surgical, Inc. | Methods and systems for characterizing fluids from a patient |
WO2016187070A1 (en) | 2015-05-15 | 2016-11-24 | Gauss Surgical, Inc. | Method for projecting blood loss of a patient during a surgery |
KR20180034619A (ko) | 2015-07-29 | 2018-04-04 | 나노틱스 엘엘씨 | 가용성 생체분자를 소거하기 위한 모듈 조성물 및 이와 관련된 방법 |
EP3374399A1 (en) | 2015-11-11 | 2018-09-19 | Opi Vi- IP Holdco LLC | Composition and methods for anti-tnfr2 antibodies |
EP3393539B1 (en) | 2015-12-23 | 2023-12-27 | Gauss Surgical, Inc. | System and method for estimating an amount of a blood component in a volume of fluid |
JP6934253B2 (ja) | 2015-12-23 | 2021-09-15 | ガウス サージカル, インコーポレイテッドGauss Surgical, Inc. | 外科織物内の血液構成要素の量の評価方法 |
DE102016106510A1 (de) * | 2016-04-08 | 2017-10-12 | ToposNomos Ltd. | Verfahren und Vorrichtung zum extrakorporalen Entfernen von pathogenen und/oder überzähligen Bestandteilen aus einer Zellprobe eines Patienten |
CN110088137A (zh) | 2016-10-19 | 2019-08-02 | 诺瓦罗技科斯生物科技有限公司 | 针对mica和micb蛋白的抗体 |
WO2018125812A1 (en) | 2017-01-02 | 2018-07-05 | Gauss Surgical, Inc. | Tracking surgical items with prediction of duplicate imaging of items |
WO2018129207A1 (en) | 2017-01-04 | 2018-07-12 | Nanotics, Llc | Methods for assembling scavenging particles |
US11229368B2 (en) | 2017-01-13 | 2022-01-25 | Gauss Surgical, Inc. | Fluid loss estimation based on weight of medical items |
WO2019053031A1 (en) * | 2017-09-13 | 2019-03-21 | Bavarian Immunology Association GmbH | PURIFIED BLOOD FOR USE IN ANTICANCER THERAPY |
EP3735281A4 (en) | 2018-01-05 | 2022-03-02 | Path Ex, Inc. | DEVICE FOR THE CAPTURE AND REMOVAL OF DISEASE MATERIAL FROM FLUIDS |
US20190247560A1 (en) * | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
US20210382035A1 (en) * | 2018-10-25 | 2021-12-09 | Tl Genomics Inc. | Pretreatment of blood for classifying blood cells using microchannel |
US20220002423A1 (en) * | 2018-11-15 | 2022-01-06 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
CN113677429B (zh) | 2019-04-26 | 2023-08-18 | 东丽株式会社 | 可溶性肿瘤坏死因子受体的吸附材料 |
CN114096278A (zh) * | 2019-05-07 | 2022-02-25 | 英谬免疫股份有限公司 | 通过体外单采血增加对检查点抑制剂的反应 |
WO2021203144A1 (en) * | 2020-04-02 | 2021-10-07 | Nuwellis, Inc. | Multi-stage blood filtration |
US11957825B2 (en) | 2021-06-17 | 2024-04-16 | Immunicom Inc. | Modified TNF as a capture ligand |
CN116492991B (zh) * | 2023-04-20 | 2024-02-23 | 江苏恰瑞生物科技有限公司 | 可清除血液中TNF-α的血液灌流器填料制备方法 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4375414A (en) * | 1971-05-20 | 1983-03-01 | Meir Strahilevitz | Immunological methods for removing species from the blood circulatory system and devices therefor |
US5643732A (en) * | 1971-05-20 | 1997-07-01 | Strahilevitz; Meir | Immunological assay methods |
US4189470A (en) * | 1973-01-30 | 1980-02-19 | Bio-Response, Inc. | Method for the continuous removal of a specific antibody from the lymph fluid in animals and humans |
US4116589A (en) * | 1977-04-15 | 1978-09-26 | Avco Corporation | Extracorporeal pulsatile blood pump comprised of side by side bladders |
US4191182A (en) * | 1977-09-23 | 1980-03-04 | Hemotherapy Inc. | Method and apparatus for continuous plasmaphersis |
USRE31688E (en) * | 1977-09-23 | 1984-09-25 | Hemotherapy, Inc. | Method and apparatus for continuous plasmapheresis |
US4439332A (en) * | 1978-08-14 | 1984-03-27 | American Cyanamid Company | Stable emulsion copolymers of acrylamide and ammonium acrylate for use in enhanced oil recovery |
US4350156A (en) * | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
US4362155A (en) * | 1981-03-24 | 1982-12-07 | Skurkovich Simon V | Method and apparatus for the treatment of autoimmune and allergic diseases |
US4824432A (en) * | 1981-03-24 | 1989-04-25 | S.V.S. Laboratories, Inc. | Method for treating AIDS and other immune deficiencies and immune disorders |
US4605394A (en) * | 1982-12-03 | 1986-08-12 | Simon V. Skurkovich | Methods for the treatment of pathological conditions by removing interferon from the organism |
US4512763A (en) * | 1981-05-04 | 1985-04-23 | Gamma Medical Products, Inc. | Method and apparatus for selective removal of constituents of blood |
US4664913A (en) * | 1982-05-24 | 1987-05-12 | Xoma Corporation | Method for treating plasma for transfusion |
US4634417A (en) * | 1982-12-06 | 1987-01-06 | Georgetown University | Process for treatment of tumors and apparatus therefor |
US4614513A (en) * | 1984-08-13 | 1986-09-30 | Fred Hutchinson Cancer Research Center | Method and apparatus for treatment to remove immunoreactive substances from blood |
US4708713A (en) | 1984-11-16 | 1987-11-24 | Anisa Medical, Inc. | Method and system for removing immunosuppressive components from the blood of mammals |
US4801449A (en) * | 1985-01-11 | 1989-01-31 | Imre Corporation | Method for treatment of Kaposi's sarcoma |
US5037649A (en) * | 1985-01-11 | 1991-08-06 | Imre Corporation | Method for treatment of HIV-infected patients |
US4863611A (en) * | 1987-04-30 | 1989-09-05 | Massachusetts Institute Of Technology | Extracorporeal reactors containing immobilized species |
US4865841A (en) * | 1987-10-23 | 1989-09-12 | Imre Corporation | Methods and compositions for transient elimination of humoral immune antibodies |
US5135919A (en) * | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
JPH07106219B2 (ja) * | 1988-08-02 | 1995-11-15 | 宇部興産株式会社 | インターロイキン2レセプターの除去装置およびそれを備えた血液体外循環装置 |
US5078673A (en) * | 1988-11-14 | 1992-01-07 | Neorx Corporation | Selective removal of radiolabeled antibodies |
US5147638A (en) * | 1988-12-30 | 1992-09-15 | Oklahoma Medical Research Foundation | Inhibition of tumor growth by blockade of the protein C system |
US7264944B1 (en) * | 1989-04-21 | 2007-09-04 | Amgen Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
US6232446B1 (en) * | 1989-05-18 | 2001-05-15 | Yeda Research And Development Co. Ltd. | TNF ligands |
US5216128A (en) * | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
US5290807A (en) * | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
EP0939121B2 (de) * | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TFN-bindende Proteine |
DE4006269A1 (de) * | 1990-02-28 | 1991-08-29 | Max Planck Gesellschaft | Antikoerper gegen den tumor-nekrosefaktor-rezeptor |
US6432405B1 (en) * | 1991-03-15 | 2002-08-13 | Duke University | Method of inhibiting HIV infection with CD44 and anti-CD44 antibodies |
ATE232730T1 (de) * | 1991-08-23 | 2003-03-15 | Alberta Res Council | Verfahren und zusammensetzungen zur verhinderung der antikörper-vermittelten abstossung von xenogenen transplantaten |
DE4331358A1 (de) * | 1992-10-12 | 1994-04-14 | Braun Melsungen Ag | Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten |
CA2149881A1 (en) * | 1992-11-19 | 1994-05-26 | Paul T. Jubinsky | Antibodies for gm-csf receptor and uses thereof |
US5910252A (en) * | 1993-02-12 | 1999-06-08 | Cobe Laboratories, Inc. | Technique for extracorporeal treatment of blood |
US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
US5626843A (en) * | 1993-02-26 | 1997-05-06 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5437861A (en) * | 1993-03-16 | 1995-08-01 | Applied Immune Sciences, Inc. | Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome |
AU680897B2 (en) * | 1993-03-16 | 1997-08-14 | Aventis Pharmaceuticals Inc. | Removal of selected factors from whole blood or its components and prevention and treatment of septic shock symdrome |
CA2119089A1 (en) * | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
US5886026A (en) * | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
US5753227A (en) * | 1993-07-23 | 1998-05-19 | Strahilevitz; Meir | Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases |
IL110787A0 (en) * | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
CN1137257A (zh) * | 1993-11-12 | 1996-12-04 | Idv经营爱尔兰公司 | 倾倒至少两种不同液体的倾倒器 |
US5639725A (en) * | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
US5705615A (en) * | 1994-10-06 | 1998-01-06 | Beth Israel Deaconess Medical Center | Antibodies specific for HTm4 |
CA2167138C (en) * | 1995-01-17 | 2000-10-31 | Keigo Arimoto | Splicing gauge |
CA2167872C (en) * | 1995-01-27 | 2007-04-03 | Masaru Nakatani | Adsorbent for removing interleukins and tumor necrosis factor, and process for removing the same |
US6428790B1 (en) * | 1995-04-27 | 2002-08-06 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
US5763415A (en) * | 1995-08-03 | 1998-06-09 | John Hopkins University School Of Medicine | Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer |
DE19538641C2 (de) * | 1995-10-05 | 2000-09-21 | Privates Inst Bioserv Gmbh | Patientenspezifische Immunadsorber für die extrakorporale Apherese und Verfahren für deren Herstellung |
EP0862444B2 (en) * | 1995-11-15 | 2014-04-09 | Edwards Lifesciences Corporation | Treatment of dilated cardiomyopathy by removal of autoantibodies |
US5861483A (en) * | 1996-04-03 | 1999-01-19 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
US6017527A (en) * | 1996-07-10 | 2000-01-25 | Immunex Corporation | Activated dendritic cells and methods for their activation |
US5869047A (en) * | 1996-10-22 | 1999-02-09 | Blake Laboratories, Inc. | Methods for therapeutically treating immunocomprised persons |
US6245038B1 (en) * | 1997-01-07 | 2001-06-12 | Helmut Borberg | Method for treatment of ophthalmological diseases |
US6221614B1 (en) * | 1997-02-21 | 2001-04-24 | The Regents Of The University Of California | Removal of prions from blood, plasma and other liquids |
US6197289B1 (en) * | 1997-07-01 | 2001-03-06 | Terumo Cardiovascular Systems Corporation | Removal of biologically active agents |
US8197430B1 (en) * | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
US6620382B1 (en) * | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
US6287516B1 (en) * | 1998-07-10 | 2001-09-11 | Immunocept, L.L.C. | Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease |
US6528057B1 (en) * | 1998-08-31 | 2003-03-04 | Julian L. Ambrus | Method for removal of HIV and other viruses from blood |
JP4638986B2 (ja) * | 1998-10-16 | 2011-02-23 | テルモ メディカル コーポレイション | 血液処理装置 |
WO2000029019A1 (en) * | 1998-11-18 | 2000-05-25 | G.D. Searle & Co. | Restoration of platelet aggregation by antibody administration after gpiib/iiia antagonist treatment |
US20010010818A1 (en) * | 1998-12-09 | 2001-08-02 | Engle Steven B. | Methods and formulations for reducing circulating antibodies |
JP2002533169A (ja) * | 1998-12-29 | 2002-10-08 | オキュロジックス コーポレイション | レオロジー的処置方法および関連するアフェレーシスシステム |
US6982089B2 (en) * | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
CA2369576C (en) * | 1999-04-23 | 2005-07-05 | William Frederick Weitzel | Extracorporeal circuit and related methods |
US6774102B1 (en) * | 1999-09-29 | 2004-08-10 | Gambro Dialysatoren Gmbh & Co. Kg | Extracorporeal endotoxin removal method |
ATE445414T1 (de) * | 1999-11-10 | 2009-10-15 | Biopheresis Technologies Inc | Verfahren und system zur entfernung von zytokininhibitoren in patienten |
US6379708B1 (en) * | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
US6890315B1 (en) * | 2000-05-23 | 2005-05-10 | Chf Solutions, Inc. | Method and apparatus for vein fluid removal in heart failure |
JP2002325837A (ja) * | 2000-06-15 | 2002-11-12 | Nefuronetto:Kk | 自動血液透析装置 |
AUPQ846900A0 (en) * | 2000-06-29 | 2000-07-27 | Aruba International Pty Ltd | A vaccine |
US20030148404A1 (en) * | 2000-07-27 | 2003-08-07 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders |
US20020058031A1 (en) * | 2000-09-19 | 2002-05-16 | Tung Hsiaoho Edward | Methods for preparing diagnostic reagents using antibody preparation |
US20020107469A1 (en) * | 2000-11-03 | 2002-08-08 | Charles Bolan | Apheresis methods and devices |
US20020086276A1 (en) * | 2000-12-28 | 2002-07-04 | Srivastava Pramod K. | Immunotherapeutic methods for extracorporeal modulation of CD36 and its ligands |
US6761700B2 (en) * | 2001-02-09 | 2004-07-13 | Orqis Medical Corporation | Extra-corporeal vascular conduit |
US20020114728A1 (en) * | 2001-02-13 | 2002-08-22 | Kulish Victor V. | Electronic Sterilizer |
US6878127B2 (en) * | 2001-04-10 | 2005-04-12 | Renaltech International, Llc | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood |
US6607501B2 (en) * | 2001-05-14 | 2003-08-19 | Reynolds G. Gorsuch | Process and apparatus for utilization of in vivo extracted plasma with tissue engineering devices, bioreactors, artificial organs, and cell therapy applications |
US6685664B2 (en) * | 2001-06-08 | 2004-02-03 | Chf Solutions, Inc. | Method and apparatus for ultrafiltration utilizing a long peripheral access venous cannula for blood withdrawal |
AU2002321760B9 (en) * | 2001-07-20 | 2008-06-12 | Absorber, Ab | Blood group antigen fusion polypeptides and methods of use thereof |
DE10144252A1 (de) * | 2001-08-31 | 2003-03-27 | Fraunhofer Ges Forschung | Nanopartikel mit daran immobilisiertem biologisch aktivem TNF |
CA2457564C (en) * | 2001-10-05 | 2009-04-07 | Surmodics, Inc. | Particle immobilized coatings and uses thereof |
AU2005240082B2 (en) * | 2004-04-30 | 2009-07-23 | Innatus Corporation | Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients |
US20070065514A1 (en) * | 2005-09-22 | 2007-03-22 | Howell Mark D | Method for enhancing immune responses in mammals |
US20080075690A1 (en) * | 2006-09-22 | 2008-03-27 | Mark Douglas Howell | Method for enhancing immune responses in mammals |
-
2005
- 2005-04-29 AU AU2005240082A patent/AU2005240082B2/en not_active Ceased
- 2005-04-29 DK DK08007944.5T patent/DK1949915T3/da active
- 2005-04-29 PL PL08007944T patent/PL1949915T3/pl unknown
- 2005-04-29 WO PCT/US2005/015037 patent/WO2005107802A2/en active Application Filing
- 2005-04-29 CA CA2565215A patent/CA2565215C/en not_active Expired - Fee Related
- 2005-04-29 CN CN2005800220636A patent/CN1980696B/zh not_active Expired - Fee Related
- 2005-04-29 JP JP2007511060A patent/JP2008511340A/ja active Pending
- 2005-04-29 EP EP05744057A patent/EP1740209A2/en not_active Ceased
- 2005-04-29 SI SI200531626T patent/SI1949915T1/sl unknown
- 2005-04-29 RU RU2006142328/14A patent/RU2378016C2/ru not_active IP Right Cessation
- 2005-04-29 PT PT08007944T patent/PT1949915E/pt unknown
- 2005-04-29 EP EP08007944A patent/EP1949915B1/en not_active Not-in-force
- 2005-04-29 US US11/119,214 patent/US20050265996A1/en not_active Abandoned
- 2005-04-29 ES ES08007944T patent/ES2393637T3/es active Active
-
2006
- 2006-10-24 IL IL178845A patent/IL178845A/en active IP Right Grant
-
2007
- 2007-10-30 US US11/929,540 patent/US20080145333A1/en not_active Abandoned
-
2009
- 2009-01-29 HK HK09100847.6A patent/HK1125026A1/xx not_active IP Right Cessation
- 2009-10-20 AU AU2009227872A patent/AU2009227872B2/en not_active Ceased
- 2009-11-02 IL IL201888A patent/IL201888A/en active IP Right Grant
- 2009-11-13 IN IN7374DEN2009 patent/IN2009DN07374A/en unknown
-
2010
- 2010-08-11 US US12/854,385 patent/US20110129441A1/en not_active Abandoned
-
2012
- 2012-05-22 US US13/477,805 patent/US20120328562A1/en not_active Abandoned
- 2012-11-14 CY CY20121101098T patent/CY1113345T1/el unknown
-
2013
- 2013-05-15 US US13/894,963 patent/US20130251672A1/en not_active Abandoned
-
2014
- 2014-09-26 US US14/498,749 patent/US20150231233A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113345T1 (el) | Μεθοδος και συστημα για την αφαιρεση διαλυτων tnfr1, tnfr2, και il2r σε ασθενεις | |
AU2018233032B2 (en) | TEC family kinase inhibitor adjuvant therapy | |
Bagnasco et al. | Anti-interleukin 5 (IL-5) and IL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma | |
Chang et al. | Medial prefrontal cortex activation facilitates re-extinction of fear in rats | |
RU2015144666A (ru) | Терапия для лечения рака, включающая антитела против клаудина 18.2 | |
WO2014142220A1 (ja) | 抗腫瘍剤 | |
US20220242963A1 (en) | B-cell activating cd73 antibodies | |
EP3075394B1 (en) | Treatment for neoplastic diseases | |
CN105050625A (zh) | 通过抗-cd3免疫毒素的免疫调节治疗没有均一地含有表面cd3的癌症 | |
CN111208283A (zh) | 增效的肿瘤抑制组合物及其应用 | |
Nampei et al. | AB0296 Discontinuation of tocilizumab after attaining remission in patients with rheumatoid arthritis | |
Sigurdardottir et al. | Early Calcineurin Inhibitors Elimination Improves Renal Function in De Novo Heart Transplant Recipients: The Results of a Randomized Controlled Trial (SCHEDULE Trial).: Abstract# 1324 | |
Chen et al. | BAFF Binding to T Cell-Expressed BAFF-R Promotes Follicular Helper T Cell Proliferation and GC B Cell Responses.: Abstract# 574 | |
Menon et al. | Inducible Knockdown of SHROOM3 Reduces Renal Fibrosis in Mice: From Bedside to Bench.: Abstract# 575 | |
He et al. | Inflammation, Immunity, Fibrosis, and Infection: Renin-angiotensin system promotes colonic inflammation by inducing TH17 activation via JAK2/STAT pathway | |
Biryukova et al. | FRI0201 Efficacyand Safety of Simvastatinin Uveitis Associated with HLAB27 and/or Rheumatic Diseases: A Randomized, Open-Label Study | |
EP4359570A1 (en) | Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer | |
Jiang et al. | Quantitative prediction of human pharmacokinetics for duvortuxizumab from cynomolgus monkey data: a translational pharmacokinetic modeling approach | |
Zoshima | Methotrexate/methylprednisolone/prednisolone | |
Fraenkel | Everolimus/mitotane interaction | |
Hernández et al. | AB0436 Do Patients Diagnosed with Chronic Inflammatory Arthropathies Treated with Rituximab Need Retreatment with the Same Dosage in Posterior Cycles? Analysis of the Sustained Response after Retreatment at A Lower Dose | |
Diana et al. | AB0437 Clinical Utility of Measuring Drug and Anti-Drug Antibody Concentration of Biologic Agents in Rheumatoid Arthritis Patients with Moderate and High Disease Activity | |
Gardette et al. | AB0298 High level of anti-ccp antibodies is predictive of good response to rituximab in patients with active rheumatoid arthritis. | |
Ragam | Adalimumab/infliximab/methotrexate | |
Joshi | Dabrafenib/trametinib |